RIME DD: strong revenue acceleration after exit from legacy business

AI Summary

Bullish DD on Algorhythm Holdings (RIME), arguing its SemCab SaaS pivot has driven rapid revenue and ARR growth with contract catalysts, though losses and pilot conversion risks remain.

RIME — LONG Author argues Algorhythm Holdings (RIME) has completed a business reset by selling The Singing Machine and focusing on SemCab, an AI-driven logistics and route optimization platform. They cite Q3 2025 revenue of about $1.7M versus $0.1M a year earlier, lower operating expenses, and SemCab ARR growth from roughly $2.5M to $9-10M, with management citing forward ARR near $15M from signed contracts. Catalysts include contract expansions with Marico (~$3M) and Hindustan Unilever ($1.6M). Main stated risk is ongoing losses and the need to convert pilots into long-term contracts.

Management has cited forward ARR near $15M based on signed contracts and expansions, indicating continued revenue visibility beyond current results.

Score 4

Comments 1

▶ Full Post Text

RIMЕ is a penny stock that recently completed a full business reset, and the financial results are starting to reflect that shift. This post focuses on operational progress and reported numbers rather than price action or trading.

Algоrhythm Holdings (RIMЕ) exited its legacy consumer electronics segment in 2025 by selling The Singing Machine business for approximately $4.5M. This allowed the company to reduce complexity and focus almost entirely on SеmiCab, its AI driven logistics and route optimization platform serving large enterprise customers. As a result, RIME is now positioned closer to a SaaS style revenue model than a hardware driven one.

The impact of this pivot is visible in reported financials. In Q3 2025, RIMЕ generated approximately $1.7M in revenue, compared with about $0.1M in the same quarter a year earlier, representing roughly 1270% year over year growth, per last 10-Q. Operating expenses declined to around $1.2M from $1.8M, and net loss narrowed to approximately $1.9M. Cash on hand at quarter end was reported at about $2.8M.

Recurring revenue metrics show additional momentum. SеmiCab annualized revenue run rate reportedly increased from roughly $2.5M early in 2025 to about $9 to $10M by year end. Management has cited forward ARR near $15M based on signed contracts and expansions, indicating continued revenue visibility beyond current results. Notable contract activity included a roughly $3M expansion with Marico and a $1.6M expansion with Hindustan Unilever, which represented more than a tenfold increase over the original pilot engagement.

RIMЕ also took steps to improve its capital structure. In early 2025, all outstanding Series B cashless warrants from a December 2024 financing were exercised, reducing balance sheet overhang and simplifying liabilities. Combined with the divestment of the legacy business, this suggests a cleaner structure focused on executing the current growth strategy.

From a business standpoint, the кey positives stand out:

* Legacy business sold for $4.5M
* Q3 2025 revenue up \~1270% year over year
* Operating expenses reduced quarter over quarter
* ARR grew from \~$2.5M to \~$9 to $10M in 2025
* Forward ARR cited near $15M from existing contracts

Risкs remain, including ongoing losses and the need to continue converting pilots into long term contracts. However, the recent data shows tangible progress rather than just a narrative shift.

Not financial advice. For those following penny stock turnarounds, does RIMЕ look like a pivot that is beginning to translate into sustainable revenue growth?

▶ Full Post Text

Ideas

More from Reddit — r/pennystocks